Rare diseases
Investigational molecules
Locations
A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity
AustriaStudy on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes
BulgariaStudy on the Effects of Semaglutide in Patients with Early Alzheimer's Disease
AustriaStudy on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3
AustriaStudy on the Effectiveness of NNC0194-0499 and Semaglutide in Treating Non-Alcoholic Steatohepatitis (NASH) in Patients with Fibrosis Stages 2-4
BelgiumStudy on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs
GreeceWeight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone
AustriaStudy comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor
GermanyA study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease
BulgariaA study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin
BulgariaA study comparing weekly insulin icodec and semaglutide with daily insulin degludec and insulin aspart in people with type 2 diabetes not well controlled on premixed insulin
PolandA study testing cagrilintide and semaglutide compared to placebo in people with type 2 diabetes not well controlled by diet and exercise
HungaryTell us about your condition – we search every trial in Europe and connect you with the right site.
